REPLIMUNE GROUP, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
REPLIMUNE GROUP, INC. (REPL) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $7.63 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-14
- REPLIMUNE GROUP, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-06-30 was $7.63, a 9.17% decline year-over-year.
- REPLIMUNE GROUP, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-06-30 was $8.40, a 8.67% increase year-over-year.
- REPLIMUNE GROUP, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-06-30 was $7.73, a 56.91% decline year-over-year.
- REPLIMUNE GROUP, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-06-30 was $17.94, a 0.77% decline year-over-year.
- REPLIMUNE GROUP, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2026 was $8.41, a 1.18% decline from fiscal 2025.
- REPLIMUNE GROUP, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $8.51, a 49.64% decline from fiscal 2024.
- REPLIMUNE GROUP, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $16.90, a 11.15% decline from fiscal 2023.
- REPLIMUNE GROUP, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $19.02, a 39.21% decline from fiscal 2022.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $7.63 10-Q · filed 2026-08-14 | |||
| 2026-03-31 | $8.41 10-K · filed 2026-06-29 | |||
| 2025-12-31 | $8.42 10-Q · filed 2026-02-03 | |||
| 2025-09-30 | $8.40 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | $8.40 10-Q · filed 2025-08-07 | |||
| 2025-03-31 | $8.51 10-K · filed 2025-05-22 | |||
| 2024-12-31 | $8.07 10-Q · filed 2025-02-12 | |||
| 2024-09-30 | $7.95 10-Q · filed 2024-11-12 | |||
| 2024-06-30 | $7.73 10-Q · filed 2024-08-08 | |||
| 2024-03-31 | $16.90 10-K · filed 2024-05-16 | |||
| 2023-12-31 | $17.92 10-Q · filed 2024-02-08 | |||
| 2023-09-30 | $18.08 10-Q · filed 2023-11-07 | |||
| 2023-06-30 | $17.94 10-Q · filed 2023-08-03 | |||
| 2023-03-31 | $19.02 10-K · filed 2023-05-18 | |||
| 2022-12-31 | $18.78 10-Q · filed 2023-02-09 | |||
| 2022-09-30 | $18.15 10-Q · filed 2022-11-03 | |||
| 2022-06-30 | $18.08 10-Q · filed 2022-08-04 | |||
| 2022-03-31 | $31.29 10-K · filed 2022-05-19 | |||
| 2021-12-31 | $32.09 10-Q · filed 2022-02-03 | |||
| 2021-09-30 | $32.49 10-Q · filed 2021-11-04 | |||
| 2021-06-30 | $32.54 10-Q · filed 2021-08-06 | |||
| 2021-03-31 | $18.10 10-K · filed 2021-05-20 | |||
| 2020-12-31 | $15.24 10-Q · filed 2021-02-04 | |||
| 2020-09-30 | $12.52 10-Q · filed 2020-11-05 | |||
| 2020-06-30 | $10.43 10-Q · filed 2020-08-07 | |||
| 2020-03-31 | $15.07 10-K · filed 2020-06-03 | |||
| 2019-12-31 | $15.00 10-Q · filed 2020-02-13 | |||
| 2019-09-30 | $15.22 10-Q · filed 2019-11-12 | |||
| 2019-06-30 | $15.42 10-Q · filed 2019-08-14 | |||
| 2019-03-31 | $14.92 10-K · filed 2019-06-28 | |||
| 2018-12-31 | $15.04 10-Q · filed 2019-02-14 | |||
| 2018-09-30 | $15.06 10-Q · filed 2018-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B |